Jardiance and Tadalafil Interaction: Safety, Risks, and Clinical Guidance

Why This Drug Combination Comes Up

Men with type 2 diabetes face erectile dysfunction (ED) at rates two to three times higher than the general population. A 2017 meta-analysis of 145 studies (N = 88,577) found a pooled ED prevalence of 52.5% among men with diabetes mellitus [1]. Empagliflozin is now prescribed across three indications (type 2 diabetes, heart failure with reduced or preserved ejection fraction, and chronic kidney disease), while tadalafil remains the most commonly prescribed PDE5 inhibitor for ED and benign prostatic hyperplasia [2]. Given the overlapping patient populations, clinicians regularly evaluate whether these two drugs can be taken together safely.

The FDA-approved prescribing information for empagliflozin does not list tadalafil as a contraindicated or dose-limiting co-medication [3]. The tadalafil label, however, carries broad warnings about blood pressure effects when combined with antihypertensives [4]. Understanding where the real clinical risk lies requires examining both the pharmacokinetic and pharmacodynamic profiles.

Pharmacokinetic Profile: No Shared Metabolic Pathway

Empagliflozin is metabolized primarily through glucuronidation by UGT1A3, UGT1A8, UGT1A9, and UGT2B7. It has minimal CYP-mediated metabolism and is neither a significant inhibitor nor inducer of CYP450 enzymes or P-glycoprotein (P-gp) at therapeutic concentrations [3]. Tadalafil, by contrast, is metabolized predominantly by CYP3A4 to a catechol metabolite that has no meaningful PDE5 inhibitory activity [4].

Because empagliflozin does not interact with CYP3A4, it will not alter tadalafil plasma concentrations. A dedicated drug interaction study in the empagliflozin clinical pharmacology program confirmed no clinically relevant changes in AUC or Cmax when empagliflozin was co-administered with substrates of major CYP isoforms [5]. Similarly, tadalafil does not inhibit UGT enzymes, so it should not affect empagliflozin clearance [4].

This pharmacokinetic independence means no dose adjustment is needed on the basis of drug metabolism alone. The clinical concern lies entirely in pharmacodynamics.

Pharmacodynamic Interaction: Additive Blood Pressure Lowering

Both drugs reduce blood pressure through distinct mechanisms. Empagliflozin lowers BP via osmotic diuresis (glycosuria-driven natriuresis), plasma volume contraction, and possibly direct vascular effects. In the EMPA-REG OUTCOME trial (N = 7,020), empagliflozin 25 mg reduced seated systolic BP by approximately 4 mmHg and diastolic BP by 1.5 mmHg compared with placebo at 12 weeks [6]. A pooled analysis of phase III data (N = 10,000+) reported systolic reductions of 3.4 to 4.2 mmHg across doses [7].

Tadalafil produces vasodilation through inhibition of PDE5 in vascular smooth muscle, increasing cyclic GMP levels. In men taking tadalafil 20 mg, mean maximal decreases in supine systolic BP were 1.6 mmHg, but when co-administered with common antihypertensive classes, reductions reached 5 to 8 mmHg in controlled studies [4]. The magnitude depends on baseline BP, concurrent antihypertensive burden, and the specific antihypertensive class used [8].

The combined effect is simple addition. A patient whose systolic BP is 128 mmHg at baseline could experience a net reduction of 8 to 13 mmHg from both drugs together. For most patients this remains clinically manageable. The risk concentrates in specific subgroups.

Who Is at Higher Risk for Hypotension

Volume-depleted patients carry the greatest risk. Empagliflozin's prescribing label warns specifically about symptomatic hypotension in patients with renal impairment, the elderly (age 75 and older), patients on loop diuretics, and those with low systolic BP at baseline [3]. The EMPA-REG OUTCOME trial reported volume depletion events in 5.1% of the empagliflozin 25 mg group versus 3.3% on placebo [6].

Adding tadalafil to this equation multiplies risk in three scenarios. First, patients already taking two or more antihypertensives alongside empagliflozin should have standing and seated BP verified before starting tadalafil [9]. Second, patients on loop diuretics (furosemide, bumetanide) face compounded volume depletion and should ensure adequate hydration [3]. Third, patients with autonomic neuropathy, which is common in longstanding diabetes, may have blunted baroreceptor reflexes and be unable to compensate for acute BP drops [10].

Patients taking alpha-blockers (tamsulosin, doxazosin) for BPH warrant particular caution. The tadalafil label advises hemodynamic stabilization on the alpha-blocker before initiating tadalafil and recommends starting at the 5 mg dose [4].

Dose Considerations and Practical Guidance

For ED treatment, tadalafil is available as 10 mg and 20 mg on-demand or 2.5 mg and 5 mg daily. Starting at the lowest effective dose (10 mg on-demand or 2.5 mg daily) is standard practice when combining with any medication that affects blood pressure [4]. This starting strategy also applies when empagliflozin is part of the regimen.

For BPH, the approved tadalafil dose is 5 mg once daily. A 12-week randomized trial (N = 511) showed tadalafil 5 mg improved International Prostate Symptom Scores by 4.87 points from baseline versus 2.27 for placebo [11]. This fixed-dose BPH indication does not permit titration, so blood pressure management must come from the other side of the equation.

For empagliflozin, the standard dose is 10 mg once daily, which can be increased to 25 mg. In the heart failure indication (EMPEROR-Preserved, N = 5,988), empagliflozin 10 mg reduced the composite of cardiovascular death or heart failure hospitalization by 21% versus placebo (HR 0.79 to 95% CI 0.69 to 0.90) [12]. If hypotension becomes an issue when tadalafil is added, reducing the empagliflozin dose from 25 mg to 10 mg is reasonable, though the diabetes benefit may be marginally reduced.

A reasonable clinical protocol: check orthostatic vitals (lying to standing, at 1 and 3 minutes) before adding tadalafil and again 48 to 72 hours after the first dose. If systolic BP drops more than 20 mmHg on standing, or the patient reports dizziness, reassess the antihypertensive stack before continuing [9].

Renal Considerations

Both drugs have renal dimensions. Empagliflozin causes an initial dip in eGFR (typically 3 to 5 mL/min/1.73 m²) within the first weeks of therapy due to tubuloglomerular feedback modulation, which is hemodynamic and generally reversible [13]. The EMPA-KIDNEY trial (N = 6,609) demonstrated a 28% reduction in the risk of kidney disease progression with empagliflozin versus placebo (HR 0.72 to 95% CI 0.64 to 0.82) [14].

Tadalafil is 36% renally excreted (as metabolites). In patients with eGFR 30 to 50 mL/min/1.73 m², the tadalafil label recommends starting at 5 mg with a maximum of 10 mg no more than once every 48 hours. Below eGFR 30, on-demand use should not exceed 5 mg every 72 hours [4]. For the daily 2.5 mg dose, no renal adjustment is specified, though careful monitoring is advised in severe impairment [4].

When both drugs are used in a patient with CKD stage 3 or 4, the additive hemodynamic effect on the afferent arteriole (empagliflozin) and systemic vasculature (tadalafil) may produce a larger-than-expected eGFR dip. Check serum creatinine and electrolytes 1 to 2 weeks after adding tadalafil in this population [15].

Hepatic Metabolism and Special Populations

Tadalafil's reliance on CYP3A4 creates interaction potential with CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin), not with empagliflozin. In patients taking a moderate CYP3A4 inhibitor (erythromycin, diltiazem, fluconazole), tadalafil AUC increases by approximately 107 to 312%, depending on the inhibitor potency [4]. If a patient is on empagliflozin, tadalafil, and a moderate CYP3A4 inhibitor simultaneously, the interaction of concern is between the CYP3A4 inhibitor and tadalafil, not between empagliflozin and tadalafil.

For patients with Child-Pugh Class A or B hepatic impairment, tadalafil exposure is comparable to healthy subjects and no dose adjustment is needed. Class C impairment has not been studied, and tadalafil should be avoided [4]. Empagliflozin AUC increases by approximately 23% in patients with severe hepatic impairment, which is not considered clinically meaningful [3].

Glycemic Effects of Tadalafil: Potential Benefit

An emerging body of evidence suggests PDE5 inhibitors may improve insulin sensitivity. A randomized placebo-controlled trial by Giannetta et al. (2012, N = 51) showed tadalafil 20 mg every other day for 12 weeks improved insulin sensitivity as measured by the HOMA-IR index in men with metabolic syndrome [16]. This effect is thought to be mediated through increased NO-cGMP signaling in skeletal muscle and improved endothelial function.

While this finding is preliminary and not reflected in the tadalafil label, it suggests that the combination with empagliflozin could theoretically have complementary metabolic effects. Clinicians should not prescribe tadalafil for glycemic benefit at this stage, but the data is reassuring that tadalafil does not worsen glucose control [17].

Nitrate Contraindication Remains Absolute

The most dangerous drug interaction in this therapeutic space is between tadalafil and organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate). This combination can produce severe, potentially fatal hypotension. The tadalafil label states that administration within 48 hours of any nitrate formulation is absolutely contraindicated [4].

Empagliflozin does not interact with the NO-cGMP pathway and does not carry a nitrate warning [3]. Patients should be specifically asked about nitrate use (including recreational amyl nitrite) before prescribing tadalafil, regardless of whether they are on empagliflozin [18].

Monitoring Protocol for the Combination

A structured approach to monitoring reduces risk without denying patients an effective ED treatment. Check baseline orthostatic vitals, serum creatinine, and electrolytes before adding tadalafil. Recheck vitals at the first follow-up (2 to 4 weeks after initiation). Educate patients on signs of hypotension: lightheadedness when standing, blurred vision on exertion, or a feeling of faintness after taking the tadalafil dose [9]. Advise adequate fluid intake (at least 1.5 to 2 liters daily), particularly during hot weather or exercise, to offset empagliflozin-induced diuresis [3]. Reassess renal function at 3 months, especially in patients with baseline eGFR <60 mL/min/1.73 m² [15].

Patients should be told to take tadalafil at a time that does not coincide with peak empagliflozin effect. Empagliflozin Cmax is reached at approximately 1.5 hours post-dose [3]. Taking tadalafil in the evening while empagliflozin is taken in the morning may modestly offset peak hemodynamic overlap, though this has not been studied in a controlled trial.